CR20200326A - Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer. - Google Patents

Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer.

Info

Publication number
CR20200326A
CR20200326A CR20200326A CR20200326A CR20200326A CR 20200326 A CR20200326 A CR 20200326A CR 20200326 A CR20200326 A CR 20200326A CR 20200326 A CR20200326 A CR 20200326A CR 20200326 A CR20200326 A CR 20200326A
Authority
CR
Costa Rica
Prior art keywords
alleviation
alzheimer
disease
prevention
treatment
Prior art date
Application number
CR20200326A
Other languages
English (en)
Inventor
Emanuele Gabellieri
Sreenivasachary Nampally
Jérôme Molette
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of CR20200326A publication Critical patent/CR20200326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Testing Relating To Insulation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La presente invención se refiere a compuestos novedosos que pueden emplearse en el tratamiento, alivio o prevención de un grupo de trastornos y anomalías asociados con los agregados de proteínas Tau (unidad asociada a tubulina) que incluyen, entre otros, los ovillos neurofibrilares (NFT), tal como la enfermedad de Alzheimer (AD).</p>
CR20200326A 2018-01-05 2019-01-04 Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer. CR20200326A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18150422 2018-01-05
EP18175852 2018-06-04
PCT/EP2019/050180 WO2019134978A1 (en) 2018-01-05 2019-01-04 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease

Publications (1)

Publication Number Publication Date
CR20200326A true CR20200326A (es) 2020-12-09

Family

ID=65010781

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200326A CR20200326A (es) 2018-01-05 2019-01-04 Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer.

Country Status (20)

Country Link
EP (1) EP3735411B1 (es)
JP (2) JP7225251B2 (es)
KR (1) KR102477105B1 (es)
CN (1) CN111757882B (es)
AU (2) AU2019205087B2 (es)
BR (1) BR112020012833A2 (es)
CA (1) CA3086759A1 (es)
CL (1) CL2020001796A1 (es)
CO (1) CO2020008287A2 (es)
CR (1) CR20200326A (es)
EC (1) ECSP20042640A (es)
IL (1) IL275781B2 (es)
JO (1) JOP20200167A1 (es)
MA (1) MA51520A (es)
MX (1) MX2020007031A (es)
NZ (1) NZ765495A (es)
PE (1) PE20211090A1 (es)
PH (1) PH12020500573A1 (es)
SG (1) SG11202005607WA (es)
WO (1) WO2019134978A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3941477A1 (en) * 2019-03-01 2022-01-26 AC Immune SA Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
CN110845457B (zh) * 2019-10-22 2022-06-10 中国药科大学 松萝酸衍生物及其制法和在阿尔茨海默病药物中的应用
CN116059192A (zh) * 2019-11-13 2023-05-05 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP2023517749A (ja) 2020-03-19 2023-04-26 エーシー イミューン エス．エー． タウオパチーの投薬治療
BR112022027107A2 (pt) * 2020-07-02 2023-03-14 Remix Therapeutics Inc Derivados de 2-(indazol-5-il)-6-(piperidin-4-il)-1,7-naftiridina e compostos relacionados como moduladores para splicing de ácidos nucleicos e para o tratamento de doenças proliferativas
KR102231446B1 (ko) * 2021-01-21 2021-03-24 (주) 와이디생명과학 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
WO2023025109A1 (zh) * 2021-08-23 2023-03-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
TW202337442A (zh) * 2022-01-05 2023-10-01 美商雷密克斯醫療公司 用於調節剪切之化合物及方法
KR20240045898A (ko) * 2022-09-30 2024-04-08 김상재 4r 타우병증의 치료 또는 예방용 펩티드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006940A (es) 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
JP2009527542A (ja) * 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害薬としての置換キナゾリン
MX2010008198A (es) * 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
JP2012512871A (ja) * 2008-12-18 2012-06-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式アザインドール
WO2011084439A1 (en) * 2009-12-17 2011-07-14 Sanofi Tetrahydrocarboline derivatives as eg5 inhibitors
CN102939282B (zh) * 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
CA2969839A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
US20180264146A1 (en) * 2015-07-15 2018-09-20 Ac Immune S.A. Novel imaging compounds
EP3118202A1 (en) * 2015-07-15 2017-01-18 AC Immune S.A. Dihydropyridopyrrole derivatives as tau-pet-ligands

Also Published As

Publication number Publication date
JP2022172130A (ja) 2022-11-15
SG11202005607WA (en) 2020-07-29
IL275781A (en) 2020-08-31
AU2019205087B2 (en) 2021-06-10
EP3735411A1 (en) 2020-11-11
AU2021203340A1 (en) 2021-06-24
BR112020012833A2 (pt) 2021-01-05
PE20211090A1 (es) 2021-06-14
AU2021203340B2 (en) 2022-11-24
IL275781B2 (en) 2024-03-01
JOP20200167A1 (ar) 2022-10-30
JP2021510151A (ja) 2021-04-15
JP7225251B2 (ja) 2023-02-20
PH12020500573A1 (en) 2021-05-10
CN111757882B (zh) 2023-08-22
IL275781B1 (en) 2023-11-01
KR20200096570A (ko) 2020-08-12
MX2020007031A (es) 2020-12-03
CA3086759A1 (en) 2019-07-11
ECSP20042640A (es) 2020-09-30
MA51520A (fr) 2021-04-14
CO2020008287A2 (es) 2020-10-30
EP3735411B1 (en) 2024-07-10
CN111757882A (zh) 2020-10-09
KR102477105B1 (ko) 2022-12-13
AU2019205087A1 (en) 2020-07-02
WO2019134978A1 (en) 2019-07-11
NZ765495A (en) 2024-02-23
CL2020001796A1 (es) 2021-01-22

Similar Documents

Publication Publication Date Title
PH12020500573A1 (en) 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer`s disease
MX2020013115A (es) Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau.
WO2020176597A9 (en) N-substituted indoles and other heterocycles for treating brain disorders
MA53937A (fr) Compositions comprenant des souches bactériennes
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
AU2015286707A8 (en) Improved A beta protofibril binding antibodies
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MY164376A (en) Phosphospecific antibodies recognizing tau
MX2017011598A (es) Metodos para tratar proteinopatias.
WO2009158467A3 (en) Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
EA201991375A1 (ru) Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми &#34;застежками-молниями&#34; (dlk), для лечения заболевания
SG10201901242PA (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
TN2017000144A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EP3773547A4 (en) IDENTIFICATION OF GRANINES AS A PATHOGENIC FACTOR OF ALZHEIMER&#39;S MORBUS AND COMPOSITIONS AND METHODS FOR INHIBITING GRANINE AGGREGATION AND TREATMENT OF ALZHEIMER&#39;S MORBUS
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
WO2018013775A3 (en) Granulin compositions and uses related thereto
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
WO2019016247A3 (en) Agents, uses and methods for treatment
MA38369A1 (fr) Peptides et compositions pour le traitement d&#39;une lesion de l&#39;articulation
WO2011045383A3 (en) 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EA202091395A1 (ru) ПРОИЗВОДНЫЕ 1,3,4,5-ТЕТРАГИДРО-2Н-ПИРИДО[4,3-b]ИНДОЛА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ, ТАКИХ КАК БОЛЕЗНЬ АЛЬЦГЕЙМЕРА
PH12021550213A1 (en) Methods for treating neurodegenerative disorders
EP4069315A4 (en) STABILIZATION OF RETROMER FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE AND OTHER NEURODEGENERATIVE DISEASES